The digital therapeutics (DTx) industry has historically faced hurdles when it comes to reimbursement, but Medicaid opportunities are now popping up. The bulk of DTx, evidence-based treatments delivered through software interventions to treat or manage a condition, focus on addressing behavioral health conditions. While the products have been on the market since 2017, reimbursement challenges […]
The Biden Administration is encouraging new digital therapeutics reimbursement strategies in both the public and private sector as part of its National Drug Control Strategy report. In the plan the White House pitches digital therapeutics, evidence-based treatments delivered through software interventions to treat or manage a condition, as a potential tool to help expand access […]
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
